Patent · US Active

Combination therapy

US9913844B2 · kind B2 · utility

7Cited by

3References

3Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Giordano Caponigro · Salt Lake City, US
Darrin Stuart · Edmonton, CA
Laure De Parseval · Basel, CH

Key dates

Filing date	Mar 19, 2014
Grant date	Mar 13, 2018
Priority date	—
Expiry date	Mar 19, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/156
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.